相关实验视频
Updated: Jun 6, 2025

13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.5K
随着时间的推移,血液中异氨基细胞数量的增加和液IL8与FEV相关1喘的减少1
S Graff1, C Moermans2, S Gerday2
1Department of Respiratory Medicine, CHU Sart-Tilman, GIGA I3 Research Group, University of Liege, GIGA +4; CHU - B34, Avenue de l'Hôpital, 11, 4000, Liège, Belgium. sgraff@chuliege.be.
Lung
|November 30, 2024
概括
血中乙氨基的增加和晚期喘发作预测成人FEV1的加速下降. 高液IL8水平也可能表明喘患者气流下降的风险增加.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 生物标志物研究 生物标志物研究
背景情况:
- 喘的特点是,强迫呼吸量在一秒内加速下降 (FEV1).
- 识别预测FEV1下降的因素对于管理喘进展至关重要.
- 皮细胞因子正在被研究为空气流量限制的潜在生物标志物.
研究的目的:
- 为了确定FEV1加速下降的预测因素,在成人喘患者.
- 评估皮细胞因子作为监测空气流量下降的潜在生物标志物.
主要方法:
- 125名成年喘患者的队列被跟踪至少5年.
- 分析了临床,功能和炎症标志物.
- 使用Luminex和ELISA测量了液中细胞因子水平 (EGF,VEGF,FGF,IL5,IL8,TGF-β,IGE).
主要成果:
- 随着时间的推移,血液中乙氨基的增加和晚些时候的喘发作独立地与加速的FEV下降有关.
- 与下降速度较慢的患者相比,加速下降的患者表现出显著更高的基线唾液IL8水平.
- 总人口的平均FEV1下降是每年预测的0.06 ± 2.44%.
结论:
- 血中乙氨基酸细胞数量的增加和晚期喘发作是加速FEV下降的确定的预测因素.
- 液中IL8水平升高可能是喘中空气流量迅速下降的危险因素.
- 唾液IL8值得进一步研究,因为它是喘进展的潜在生物标志物.
相关概念视频
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma: Pathogenesis and Management
351
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
351
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K

